Bempedoic Acid/Ezetimibe

贝派度酸/依折麦布

Report date: 2025/05/21 11:38:36

Base Information

Drug NameBempedoic Acid/Ezetimibe
Drug Alias NameEzetimibe/Bempedoic AcidBempedoic Acid and EzetimibeEzetimibe and Bempedoic AcidNexlizetNustendi
ClassificationSmall molecules
Mechanisms of ActionATP-citrate synthase inhibitorsCholesterol absorption inhibitorsNiemann-Pick C1-like protein 1 inhibitors
TargetsATP-citrate synthaseNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaDyslipidemias +[4] 
Global Approved IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaDyslipidemias +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2020/02/26
Country/TerritoryUnited StatesEU
CombinationsYes Bempedoic AcidEzetimibe
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEsperion
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo Europe GmbhEsperion Therapeutics IncOtsuka Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaDyslipidemias +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeC10BA
Related LinksN/A